Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03773549 · ClinicalTrials.gov registry record
A Virtual Reality Study of Cognitive Biases in Body Dysmorphic Disorder
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 58
- Enrollment target
NCT03773549: Completed study, sponsored by Massachusetts General Hospital.
NCT03773549 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03773549 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 58 participants
- Enrollment target
Study Summary
Previous research shows that individuals with Body Dysmorphic Disorder (BDD) misinterpret ambiguous social information in a negative and threatening manner. These erroneous threat appraisals are thought to maintain disorder symptomatology and psychosocial impairment by reinforcing individuals' distorted self-image and ideas of social undesirability. Thus, maladaptive interpretation biases represent an important treatment target for this population; however, existing bias assessments and modification protocols are limited by the hypothetical and distal nature of scenarios and do not capture momentary experiential threat processes. The proposed study seeks to test virtual reality (VR) technology as a novel, in vivo means of eliciting, identifying, and measuring threat interpretation biases in a clinical sample to better understand the fear/threat structure activated during social interactions in BDD. Findings have the potential to enhance our understanding of disorder maintenance and identify more nuanced treatment targets. This study represents a critical first step in the long-term goal of harnessing VR gaming technology to supercharge existing treatment approaches for this debilitating illness.
Primary Outcome
Assessed by using iMotions software to measure heart rate (HR) while watching the virtual reality scenes. We hypothesize that compared to healthy controls, participants with BDD will show greater reactivity/arousal via HR measurements for these socially ambiguous scenarios.
Interventions
- OTHER Virtual reality experience
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2019-09-20 |
What the finished NCT03773549 record still lists
NCT03773549 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Virtual reality experience is the first listed.
NCT03773549 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03773549 about?
NCT03773549 is a clinical study titled "A Virtual Reality Study of Cognitive Biases in Body Dysmorphic Disorder". Previous research shows that individuals with Body Dysmorphic Disorder (BDD) misinterpret ambiguous social information in a negative and threatening manner. These erroneous threat appraisals are thought to maintain disorder symptomatology and psychosocial impairment by reinforcing individuals' disto...
What is the current status of trial NCT03773549?
This trial is currently completed. The enrollment target is 58 participants. The study started on 2019-03-01. Estimated completion is 2019-09-20.
What interventions are being tested in trial NCT03773549?
The interventions under investigation include: Virtual reality experience (OTHER).
Who is sponsoring clinical trial NCT03773549?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI